Yatabe, 2011 [22] | Resected lung adenocarcinoma with EGFR mutation | 50/3 5/>100 | Cycleave PCR/FA | Manual MD | 100 | NA | 0 | NA |
Sun, 2012 [23] | Early-stage mixed adenocarcinoma | 10/2–3 | DS | Manual MD | 80 | 20 | 0 | NA |
Mattsson, 2012 [24] | Resected NSCLC with EGFR mutation | 6/3 | DS | Manual MD | 100 | NA | 0 | NA |
Jiang, 2008 [17] | Stage IIIB/IV EGFR mutated gefitinib-responsive NSCLC with AR | 6/11–32 | DS | Laser MD | 50 | NA | 50 | NA |
Taniguchi, 2008 [18] | Resected NSCLC treated with gefitinib for postoperative recurrence | 21/50–60 | SNaP shot | Laser MD | 71.4 | NA | 28.6 | 18 months for group A versus 7.5 months for group C |
Bai (2012) [19] | Stage III/IV NSCLC with palliative resection | 79/30–40 | DHPLC/ARMS | Laser MD | 20.3 | 41.8 | 38 | NA |
Bai, 2013 [20] | Stage III/IV NSCLC with palliative resection | 85/total 2699 areas | DHPLC/ARMS | Laser MD | 24.7 (DHPLC) 36.5 (ARMS) | 42.4 (DHPLC) 35.3 (ARMS) | 32.9 (DHPLC) 28.2 (ARMS) | 16 months for group A versus 11 months for group C versus 3 months for group B |
Tomonaga, 2013 [21] | Stage I resected mixed adenocarcinoma | 38/NA | RFLP | Laser MD | 26.3 | 50 | 24 | NA |